Analysts tap Amgen, Celgene as potential 2012 dealmakers

Analysts are saying the world's biggest biotechs, including Amgen ($AMGN) and Celgene ($CELG), are likely to scout for big acquisitions this year as they seek to revive growth and refill pipelines, Bloomberg reports. Report

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.